Furthermore the ability of steroidal nuclear receptor such as the AR and ERα to bind NCOR1 and NCOR2/SMRT is important to therapeutic exploitation with receptor antagonists in prostate and breast cancer. This evidence concerns the gene NCOR2 and breast carcinoma.